在血液癌症和高血压/心脏影响中使用VEGF抑制剂
Jatin Thukral1, Harbir Kaur2, Ninaad Sindhwani3
1From the Department of Internal Medicine, New York Medical College/Landmark Medical Centre, Woonsocket, RI.
Cardiology in review
|February 25, 2026
概括
抑制血管内皮生长因子 (VEGF) 的向疗法正在改变血液癌症治疗. 然而,VEGF抑制剂可能会导致显著的心血管毒性,给脆弱患者带来挑战.
科学领域:
- 心脏瘤学 - 心脏瘤学
- 血液学恶性瘤是什么
- 有针对性的癌症治疗方法
背景情况:
- 血液性恶性瘤越来越多地使用向治疗来治疗.
- 血管内皮生长因子 (VEGF) 信号抑制剂最初用于固体瘤,现在用于血液癌症.
- 在血管生成和血管完整性中,VEGF起着至关重要的作用.
研究的目的:
- 在血液癌症的背景下审查VEGF生物学.
- 讨论用于治疗这些恶性瘤的VEGF向药物.
- 概述与这些药物相关的心血管毒性机制.
主要方法:
- 文献审查的重点是血液恶性瘤中的VEGF信号.
- 与VEGF抑制剂相关的心血管不良事件的分析.
- 检查这个人群中患者的弱点.
主要成果:
- 抑制VEGF会导致可预测的心血管毒性,如高血压和心力衰竭.
- 血液癌症患者可能对这些毒性增加了敏感性.
- 了解这些机制是临床管理的关键.
结论:
- VEGF抑制剂为血液癌症提供了新的治疗途径.
- 心血管不良影响是一个重大的临床挑战.
- 心脏瘤学策略对于接受VEGF向治疗的患者的管理至关重要.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.3K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.3K
Regulation of Angiogenesis and Blood Supply
3.8K
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
3.8K
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
508
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
508
Antihypertensive Drugs: Direct Renin Inhibitors
1.6K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.6K
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
2.7K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.7K
Heart Failure V: Medical Management
400
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
400


